Singapore: Sundia MediTech, a China-based CRO company, appointed Mr Albert Liou, Mr Haibo Wang, and Ms Wilma Wei as independent board members to its board of directors, effective immediately. These appointments will expand the company's board from four to seven members. The Sundia board of directors is responsible for the direction, strategy, organization and administration of the company.

"We are very pleased to welcome our independent board members. They bring a strong track record in pharmaceutical industry, financial community and corporate management, as well as a global outlook together with in-depth knowledge of business operation," said Ms Cathy Yen, chairman of Sundia, who took the helm of the board in February. "I am sure their experience and insight will greatly assist us in the future development of the group to better serve our customers as well as in the establishment of policies and practices to support stronger corporate governance," she added.

Mr Albert Liou serves as the chairman of Fidelitas International, engaging in the investment of biotech medical equipment industry. He also serves as the chairman of ARDIC Instruments focusing on pipeline of analytical instruments for educational, research, and industrial applications in nanotechnology and is the vice president of PAREXEL International, a leading global biopharmaceutical service organization, with main duties focusing on client relationships, business development and strategic initiatives in 13 countries in the Asia Pacific region including Taiwan, China, Japan, Korea, Singapore, and India. Mr Liou has over 25 years of clinical research experience, of which 11 years were spent in the US and 14 years in Asia.

Mr Haibo Wang is the president and CEO of Fudan-Zhangjiang Bio-Pharmaceutical, where he oversees all the company's businesses and divisions. He is also the chairman of FDZJ's board of directors. Prior to FDZJ, Mr Wang served as the supervisor of Pudong Productivity Promotion Center and associate professor of Fudan University. He has also worked for Zhejiang Shenghua Biok Biology, a listed company in the PRC, serving as the chief technology officer. He presided over the new drug for R&D and development, including Avermectin, Maduramicin and Ivermectin. Now, he serves as the expert of National Significant Creation of new drugs.

Ms Wilma Wei received her MBA from University of Washington in Seattle in 1980s. Her career started from financial industry with experiences in cross border M&A, fund raising and structured finance. She was CFO of an electronic company for 10 years and she is now in charge of strategic investment in one of the reputable electronic companies in Taiwan.